Table 3. Univariate analysis- EFS of whole, localised and metastatic cohorts.

Variable	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
	For whole cohort (n = 52)			For localised cohort (n = 43)			For metastatic cohort (n = 9)
Gender (Male versus Female)	1.2	0.4–3.6	0.7	2.1	0.69–6.6	0.18	3.35	0.40–27.9	0.3
Age (>10 years versus £10 years)	1.85	0.76–4.5	0.17	1.25	0.39–4.4	0.7	1.58	0.35–7.1	0.55
Site of primary (BP versus others)	1.46	0.63–3.38	0.37	1.9	0.66–5.5	0.22	1.17	0.26–5.3	0.83
Histology (ARMS versus ERMS)	1.53	0.36–6.59	0.56	-	-	-	-	-	-
Lymph node involvement	2.08	0.9–4.7	0.08	1.69	0.63–4.5	0.29	5.4	0.95–30.8	0.057
Group (IV versus localised)	3.2	1.3–7.8	0.019	-	-	-	-	-	-
Radiotherapy > 20.5 weeks from start of chemotherapy	2.26	0.8–6.4	0.123	3.34	0.89–12.4	0.07	0.71	0.06–8	0.78
tsize > 5 cm	2.22	0.86–5.74	0.09	2.5	0.8–8.1	0.11	0.88	0.17–4.5	0.87
tsize > 6.45 cm	3.6	1.45–8.98	0.006	4.1	1.38–12.1	0.01	0.87	0.17–4.5	0.87
Post definitive radiotherapy PET FDG-avid residual	-	-	0.2	9.35	0.84– 103.9	0.06	-	-	0.4
Local therapy (RT versus Surgery)	0.88	0.25–3.14	0.8	1.7	0.33–8.79	0.5	0.04	0.00–0.78	0.034